Published in Drug Week, January 6th, 2006
Hycamtin is the first drug to receive a positive opinion from the CHMP for the treatment of relapsed SCLC, according to the company.
The CHMP's positive opinion will now be proposed for final marketing approval by the European Commission. The product previously received approval in Europe for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.